TP53 and colorectal cancer: These results suggest that pKAL-induced cell death may not be significantly inhibited by NAC in p53 wild-type HCT116 colorectal cancer cells because p53-dependent cell death signaling activated by pKAL is enhanced by the co-treatment of NAC.